Impact of Resveratrol and Pharmaceutical Care on Type 2 Diabetes Mellitus and Its Neuropathic Complication: A Randomized Placebo Controlled Clinical Trial

Table 4

Severity of diabetic neuropathy assessed by Michigan Neuropathy Screening Instrument (MSNI)-history scores of patients with diabetic neuropathic pain before and after administration of resveratrol with and without pharmaceutical care compared to placebo.

Duration (day)

Resv (n, %), total n = 25

Placebo (n, %), total n = 23

Resv + PC (n, %), total n = 25

Placebo + PC (n, %), total n = 24

≤4

5-6

>7

≤4

5-6

>7

≤4

5-6

>7

≤4

5-6

>7

Day-0

(0) 0^a

(5) 20^a

(20) 80^a

(0) 0^a

(4) 17^a

(19) 83^a

(0) 0^a

(5) 20^a

(20) 80^a

(0) 0^a

(1) 4^a

(23) 96^a

Day-30

(0) 0^a

(7) 28^a

(18) 72^a

(0) 0^a

(4) 17^a

(19) 83^a

(7) 28^b

(8) 32^a

(10) 40^b

(0) 0^a

(5) 21^a

(19) 79^a

Day60

(8) 32^a

(12) 48^a

(5) 20^a

(0) 0^b

(5) 22^a

(18) 78^b

(15) 60^a

(7) 28^a

(3) 12^a

(0) 0^b

(4) 17^b

(20) 83^b

Day-90

(14) 56^a

(9) 36^a

(2) 8^a

(0) 0^b

(4) 17^a

(19) 83^b

(15) 60^a

(7) 28^a

(3) 12^a

(0) 0^b

(7) 29^a

(17) 71^b

Values are expressed as number (n) and percentage (%). Chi-square test was used to compare the different groups. Statistical significance was set at value <0.05. <0.05, <0.001, and <0.0001. MNSI: Michigan Neuropathy Screening Instrument. Significantly different compared to baseline within the same group ; values with nonidentical superscripts (a, b) are significantly different among different groups within the same time . Resv, resveratrol and PC, pharmaceutical care.